The DOI matches its Crossref record; 889 of the 893 references it cites were found in a registry or an index, and 4 are not checked yet.
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Open accessAbstract
The individual reviewers' relationships with industry information is available in Appendix 2.This document was approved for publication by the governing bodies of the ASA and the AHA.It was reviewed for evidence-based integrity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with CKM stage 1 due to overweight and obesity are at increased risk for developing metabolic risk factors and CKD compared with those who have a normal weight without risk factors (CKM stage 0).5,6,41”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in the absence of these metabolic risk factors, excess weight is associated with increased cardiovascular risk, particularly for HF.6,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a particular focus on preventing the development of excess and dysfunctional adipose tissue because the emergence of metabolic risk factors from youth and young adulthood into middle age is primarily related to weight gain with aging.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adults with overweight or obesity who have significant barriers to participating in multicomponent behavioral weight loss interventions, self-directed digital health solutions can be beneficial to promote weight loss for CKM syndrome risk reduction.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among patients with CKM stage 1 to 3 and obesity without an adequate weight loss response to lifestyle modification, with or without the use of adjunctive obesity pharmacotherapies, MBS can be beneficial to facilitate weight loss and to mitigate CKM syndrome progression.1–8”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glycemia consistently improves with use of these agents, with some evidence for preventing progression to diabetes in those with insulin resistance.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS has efficacy among individuals with a BMI ≥35 kg/m2 regardless of the presence of comorbidities and can be beneficial in patients with T2D with a threshold BMI of 30 kg/m2.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Counseling on dietary or combined dietary and exercise modifications effectively facilitates weight loss in postpartum women with GDM.6,19–21”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RASi provide BP control and kidney and cardiovascular protection6 and are therefore preferred in patients with CKD and albuminuria.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials and meta-analyses of SGLT2i in patients with CKD and T2D or CKD and UACR ≥200 mg/g without T2D have shown a significant reduction in risks of losing kidney function, kidney failure, cardiovascular death, and HF hospitalization when compared with placebo.5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of subclinical atherosclerosis (eg, elevated CAC) is associated with an increased cardiovascular risk among those with CKM risk factors (eg, diabetes, CKD).5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MBS is associated with a lower risk of incident major adverse liver outcomes and MACE in large cohort studies.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a 60% increased risk of stroke recurrence.35”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Standard stroke care includes medical treatment, routine stroke therapy, and rehabilitative exercises, as outlined in the basic guidelines [35,36].”
From Smartphone-Based Speech Therapy for Poststroke Dysarthria: Pilot Randomized Controlled Trial Evaluating Efficacy and Feasibility (2024) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, current guidelines recommend short-term dual antiplatelet therapy after high-risk transient ischemic attack and minor stroke (198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [198]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, owing to the chronicity of obesity and multiple compensatory changes in metabolism, hunger, and satiety promoting weight recidivism,6 frequent and long-term engagement and behavioral support for lifestyle modification are needed for optimal effectiveness.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, as per clinical guidelines, persistently elevated triglycerides are considered a risk enhancer for ASCVD.2,4–6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CAC assessment improves prediction of ASCVD4,5 and selection of patients for treatment with aggressive ASCVD risk factor modification (ie, statin therapy).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CorCal (Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of CAC Screening, in Preventing Future MACE)6 randomized 601 primary prevention patients to CAC (n=302) or risk calculator guidance (n=299) for primary prevention; the CAC arm had a greater reclassification of risk compared with the group using a risk calculator.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At 1 year, statin adherence was superior, low-density lipoprotein cholesterol (LDL-C) levels were lower, and estimated costs were similar or reduced in the CAC arm.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Once obesity is established, multiple compensatory mechanisms impacting metabolism, hunger, and satiety are triggered in the setting of intentional weight loss, which commonly result in weight regain.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In EMPA-Kidney, the risk reduction for the primary outcome (a composite of progression of kidney disease or death from cardiovascular causes) with empagliflozin compared with placebo was larger among patients with higher UACR (UACR ≥30–300: HR, 0.91; 95% CI, 0.65–1.26 versus UACR ≥300: HR, 0.67; 95% CI, 0.58–0.78).6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the rate of eGFR decline after the initial decrease was slower in the empagliflozin group than in the placebo group in all key subgroups, including in the subgroup of patients with a UACR <30 mg/g.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Simulation studies suggest that combinations of CKM therapies may have additive benefits for heart and kidney protection.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the SELECT trial,6 17 604 participants with BMI ≥27 kg/m2 and established ASCVD (prior MI, stroke, or symptomatic PAD), and without T2D, end-stage kidney disease, or dialysis, were enrolled. The trial demonstrated a 20% reduction in risk of the composite primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke for those treated with semaglutide (2.4 mg) as compared with placebo”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A single-arm 15-week pragmatic weight management program (weekly consultations with exercise specialists, dietitians, and behavioral specialists), achieved a mean weight loss of 8.1 kg (−6.7%) for patients with obesity-related HFpEF.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients with HFrEF, RASi improves both HF outcomes and risk for worsening kidney disease in several clinical trials.1–8,28”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A directionally similar reduction in risk of the cardiovascular outcome (cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for HF) was observed in a subgroup with CKD G4 in the FIDELITY meta-analysis of finerenone in diabetic patients, but this was nonsignificant and requires further investigation.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Metabolic and bariatric surgery causes remission of MASLD, even in advanced stages.6,24,25”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hyperkalemia was more frequent in those with CKD G4 treated with finerenone.6”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Abdominal adiposity is one of the strongest VTE risk factors.3,5–7”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes.”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“the American Heart Association/American Stroke Association guideline suggests GLP-1RAs as second-line to metformin regardless of baseline HbA1c in individuals with established atherosclerotic CVD to avoid further vascular events 7”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
In the citing paper
“In the same vein, the 2020 Canadian Stroke Best Practices update for secondary prevention of stroke, 8 2021 Spanish Society of Neurology consensus statement, 9 2021 American Heart Association/American Stroke Association Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack, 7 and the Diabetes, Cardiorenal, and Metabolic Diseases Multispecialty Task Force 55”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Albay, C. E. Q., Leyson, F. G. D., & Cheng, F. C. (2020) · BMC Neurology · doi:10.1186/s12883-020-01808-y · Cited by 22
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Research works printed but not linked: 11
- 10.1148/radiol.10100804 · DOI
- 10.1001/jama.1988.03720070025028 · DOI
- 10.1161/JAHA.117.00785 · DOI
- Inzucchi, SE, Docherty, K, Kober, L, Kosiborod, MN, Martinez, F. Effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from DAPA-HF. Paper presented at: American Diabetes Association 80th Scientific Sessions; 2020; virtual.
- 10.1161/JAHA.116.00472 · DOI
- 10.1056/NEJMoa1910355 · DOI
- 10.1136/bmj.324.7329.7 · DOI
- 10.1182/blood.V63.1.162.162 · DOI
- 10.1043/0003-9985(2002)126<0182:AFIAHI>2.0.CO;2 · DOI
- Ubogu, EE, Zaidat, OO. Vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography and risk of stroke and death: a cohort study. J Neurol Neurosurg Psychiatry. 2004;75:22–26.
- Lawrence, K, Keleher, T. Structural Racism. Paper presented at: Race and Public Policy Conference; November 11–13, 2004; Berkeley, CA.
Cited by
Sorted by citations
Items 101–200 of 1,000
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Ahluwalia, K., Ebright, B., Chow, K. V., Dave, P., Mead, A., Poblete, R. A., Louie, S. G., & Asante, I. (2022) · Metabolites · doi:10.3390/metabo12040333 · Cited by 56
Kim, H. W., Regenhardt, R. W., D’Amato, S. A., Nahhas, M. I., Dmytriw, A. A., Hirsch, J. A., Silverman, S. B., & Martínez-Gutiérrez, J. C. (2022) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2022-018732 · Cited by 54
New insights into the roles of oligodendrocytes regulation in ischemic stroke recovery
Huang, S., Ren, C., Luo, Y., Ding, Y., Ji, X., & Li, S. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106200 · Cited by 54
Kang, C., Sang, Q., Liu, D., Wang, L., Li, J., & Liu, X. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00828-5 · Cited by 55
Shoamanesh, A., Field, T. S., Coutts, S. B., Sharma, M., Gladstone, D. J., Hart, R. G., Boriani, G., Wright, D. J., Sticherling, C., Birnie, D. H., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00475-7 · Cited by 53
Asundexian for Secondary Stroke Prevention
Sharma, M., Dong, Q., Hirano, T., Kasner, S. E., Saver, J. L., Masjuán, J., Demchuk, A. M., Cordonnier, C., Bereczki, D., Tsivgoulis, G. K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513880 · Cited by 68
Nguyen, A. B., Cavallari, L. H., Rossi, J. S., Stouffer, G. A., & Lee, C. R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991646 · Cited by 52
Functional Ability and Health Problems of Stroke Survivors: An Explorative Study
Poomalai, G., Prabhakar, S., & Jagadesh, N. S. (2023) · Cureus · doi:10.7759/cureus.33375 · Cited by 52
Bhatia, K., Ladd, L., Carr, K., Napoli, M. D., Saver, J. L., McCullough, L. D., Farahabadi, M. H., Alsbrook, D. L., Hinduja, A., Ortiz-Garcia, J., et al. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01266-2 · Cited by 57
Future of Endovascular and Surgical Treatments of Atherosclerotic Intracranial Stenosis
Elder, T. A., White, T. G., Woo, H. H., Siddiqui, A. H., Nunna, R. S., Siddiq, F., Esposito, G., Chang, D., Gonzalez, N. R., & Amin‐Hanjani, S. (2024) · Stroke · doi:10.1161/strokeaha.123.043634 · Cited by 51
Zhou, X., Chen, K., Hu, Y., & Wang, X. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1021378 · Cited by 53
Antiplatelet strategies: past, present, and future
Stanger, L., Yamaguchi, A. A., & Holinstat, M. A. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.013 · Cited by 55
Brazilian Academy of Neurology practice guidelines for stroke rehabilitation: part I
Minelli, C., Bazán, R., Pedatella, M. T. A., Neves, L. D. O., Cacho, R. D. O., Magalhães, S. C. S. A., Luvizutto, G. J., Moro, C. H. C., Lange, M. C., Módolo, G. P., et al. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2021-0354 · Cited by 56
Secondary Ischemic Stroke Prevention
Bangad, A., Abbasi, M., & de Havenon, A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01352-w · Cited by 60
di Biase, L., Bonura, A., Pecoraro, P. M., Carbone, S. P., & Lazzaro, V. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411545 · Cited by 48
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Capodanno, D., Alexander, J. H., Bahit, M. C., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Kunadian, V., Lip, G. Y. H., Lópes, R. D., Mehran, R., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01144-z · Cited by 57
Patent Foramen Ovale and Stroke
Kent, D. M., & Wang, A. Y.-D. (2025) · JAMA · doi:10.1001/jama.2025.10946 · Cited by 48
Carotid webs: a review of pathophysiology, diagnostic findings, and treatment options
Chen, H. A., Colasurdo, M., Costa, M. L., Nossek, E. Z., & Kan, P. T. M. (2024) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2023-021243 · Cited by 47
Krishnan, K., Nguyen, T. N., Appleton, J. P., Law, Z. K., Caulfied, M. J., Cabrera, C., Lenthall, R., Hewson, D. W., England, T. J., McConachie, N. S., et al. (2023) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.122.000576 · Cited by 54
Self-citationAlperi, A., Guedeney, P., Horlick, E. M., y, L. N.-F., Freixa, X., Pascual, I., Mesnier, J., Houde, C., Abrahamyan, L., Montalescot, G., et al. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011652 · Cited by 45
Niculescu, R., Russu, E., Arbănași, E. M., Kaller, R., Arbănași, E. M., Melinte, R. M., Coșarcă, C. M., Cocuz, I. G., Sabău, A.-H., Tinca, A. C., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113934 · Cited by 45
Cancer-Associated Stroke: Thrombosis Mechanism, Diagnosis, Outcome, and Therapeutic Strategies
Heo, J. H., Yun, J., Kim, K. H., Jung, J. W., Yoo, J., Kim, Y. D., & Nam, H. S. (2024) · Journal of Stroke · doi:10.5853/jos.2023.03279 · Cited by 49
The Swiss Brain Health Plan 2023–2033
Bassetti, C. L., Heldner, M. R., Adorjan, K., Albanese, E., Allali, G., Arnold, M., Bègue, I., Bochud, M., Chan, A., Kim, Q., et al. (2023) · Clinical and Translational Neuroscience · doi:10.3390/ctn7040038 · Cited by 46
Self-citationGreenberg, S. M., Aparicio, H. J., Furie, K. L., Goyal, M. S., Hinman, J. D., Kozberg, M. G., Leonard, A., & Fisher, M. (2024) · Stroke · doi:10.1161/str.0000000000000480 · Cited by 44
Merkler, A. E., Pearce, L. A., Kasner, S. E., Shoamanesh, A., Birnbaum, L., Kamel, H., Sheth, K. N., & Sharma, R. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3828 · Cited by 44
Self-citationNeurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Hale, E., Gottlieb, E., Usseglio, J., & Shechter, A. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.02.019 · Cited by 44
Advances in the management of cardioembolic stroke associated with patent foramen ovale
Grory, B. M., Ohman, E. M., Feng, W., Xian, Y., Yaghi, S. R., Kamel, H., & Reznik, M. E. (2022) · BMJ · doi:10.1136/bmj-2020-063161 · Cited by 43
Self-citationDusenbury, W., Mathiesen, C., Whaley, M., Adeoye, O. M., Leslie‐Mazwi, T. M., Williams, S., Velasco, C., Shah, S. P., Gonzales, N. R., & Alexandrov, A. W. (2023) · Stroke · doi:10.1161/str.0000000000000424 · Cited by 42
Wang, S., Pan, Y., Zhang, C., Zhao, Y., Wang, H., Ma, H., Sun, J., Zhang, S., Yao, J., Xie, D., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04210-8 · Cited by 44
Vessel Wall Magnetic Resonance Imaging in Cerebrovascular Diseases
Mazzacane, F., Mazzoleni, V., Scola, E., Mancini, S., Lombardo, I., Busto, G., Rognone, E., Pichiecchio, A., Padovani, A., Morotti, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020258 · Cited by 42
Craniocervical Artery Dissections: A Concise Review for Clinicians
Keser, Z., Meschia, J. F., & Lanzino, G. S. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.02.007 · Cited by 42
Self-citationCollateral Flow in Intracranial Atherosclerotic Disease
Leng, X., & Leung, T. W. H. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01042-3 · Cited by 41
Minh, H. V., Huy, T. V., Doan, L., & Tien, H. A. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14580 · Cited by 44
Mayerhofer, E., Strecker, C., Becker, H., Georgakis, M. K., Uddin, M. M., Hoffmann, M. M., Nadarajah, N., Meggendorfer, M., Haferlach, T., Rosand, J., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041416 · Cited by 41
Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 49
Risk of recurrent stroke in Rotterdam between 1990 and 2020: a population-based cohort study
Berghout, B. P., Bos, D., Koudstaal, P. J., Ikram, M. A., & Ikram, M. K. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100651 · Cited by 45
Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke
Khan, F., Yogendrakumar, V., Lun, R., Ganesh, A., Barber, P. A., Lioutas, V., Vinding, N. E., Algra, A., Weimar, C., Ögren, J., et al. (2025) · JAMA · doi:10.1001/jama.2025.2033 · Cited by 41
Bae, H., Kim, J. Y., Kang, J., Kim, B. J., Han, M., Choi, K., Kim, J., Park, M., Cho, K., Kim, B.-K., et al. (2022) · Stroke · doi:10.1161/strokeaha.122.039212 · Cited by 40
Pan, Y., Meng, X., Yuan, B., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00113-8 · Cited by 40
COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older
Yang, Q., Tong, X., George, M. G., Chang, A., & Merritt, R. K. (2022) · Neurology · doi:10.1212/wnl.0000000000013184 · Cited by 40
Aggarwal, D., Bhatia, K., Chunawala, Z. S., Furtado, R. H. M., Mukherjee, D., Dixon, S. R., Jain, V., Arora, S., Zelniker, T. A., Navarese, E. P., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac019 · Cited by 40
Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke
Xian, Y., Xu, H., Matsouaka, R., Laskowitz, D. T., Maisch, L., Hannah, D., Smith, E. E., Fonarow, G. C., Bhatt, D. L., Schwamm, L. H., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.24157 · Cited by 39
Nakai, M., Iwanaga, Y., Sumita, Y., Wada, S., Hiramatsu, H., Iihara, K., Kohro, T., Komuro, I., Kuroda, T., Matoba, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264390 · Cited by 39
Sato, F., Nakamura, Y., Kayaba, K., & Ishikawa, S. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.05.002 · Cited by 40
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke
Mittal, P., Quattrocchi, G., Tohidi‐Esfahani, I., Sayar, Z., Chandratheva, A., & Cohen, H. (2022) · International Journal of Stroke · doi:10.1177/17474930221150349 · Cited by 41
Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
Tatuene, J. K., Nomani, A. Z., Falcione, S. R., Munsterman, D., Sykes, G. P., Joy, T., Spronk, E., Vargas, M. I., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.719329 · Cited by 40
Youssef, A. A., Alrefae, M. A., Khalil, H. H., Abdullah, H. I., Khalifa, Z. S., Shaban, A. A. A., Wali, H. A., AlRajab, M. R., Saleh, O. M., & Nashy, B. N. E. (2022) · CJC Open · doi:10.1016/j.cjco.2022.12.003 · Cited by 38
Fanning, J. P., Campbell, B. C. V., Bulbulia, R. A., Gottesman, R. F., Ko, S., Floyd, T. F., & Messe, S. R. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00487-6 · Cited by 39
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 38
Dharmakulaseelan, L., & Boulos, M. I. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.04.028 · Cited by 47
Stroke–heart syndrome: current progress and future outlook
Wang, L.-J., Ma, L., Ren, C., Zhao, W.-B., Ji, X.-M., Liu, Z., & Li, S.-J. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12480-4 · Cited by 41
Brazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 102
Deep learning-based reconstruction can improve the image quality of low radiation dose head CT
Nagayama, Y., Iwashita, K., Maruyama, N., Uetani, H., Goto, M., Sakabe, D., Emoto, T., Nakato, K., Shigematsu, S., Kato, Y., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09559-3 · Cited by 38
Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome
Thomas, R. G., Kim, J., Kim, J., Yoon, J., Choi, K., & Jeong, Y. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01125-9 · Cited by 37
Associations Between Vascular Risk Factor Levels and Cognitive Decline Among Stroke Survivors
Levine, D. A., Chen, B., Gałecki, A. T., Gross, A. L., Briceño, E. M., Whitney, R. T., Ploutz-Snyder, R. J., Giordani, B., Sussman, J. B., Burke, J. F., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.13879 · Cited by 38
Święczkowski, M., Lip, G. Y. H., Kurasz, A., Dąbrowski, E. J., Tomaszuk−Kazberuk, A., Kaminski, J. W., Strużewska, J., Dobrzycki, S., & Kuźma, Ł. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae301 · Cited by 37
Operationalising treatment success in aphasia rehabilitation
Breitenstein, C., Hilari, K., Menahemi-Falkov, M., Rose, M. L., Wallace, S. J., Brady, M., Hillis, A. E., Kiran, S., Szaflarski, J. P., Tippett, D. C., et al. (2022) · Aphasiology · doi:10.1080/02687038.2021.2016594 · Cited by 37
Duplex ultrasound for diagnosing symptomatic carotid stenosis in the extracranial segments
Cassola, N., Baptista-Silva, J. C., Nakano, L. C. U., Flumignan, C. D. Q., Sesso, R., Vasconcelos, V., Carvas, N., & Flumignan, R. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013172.pub2 · Cited by 47
Smartphone App in Stroke Management: A Narrative Updated Review
Bonura, A., Motolese, F., Capone, F., Iaccarino, G., Alessiani, M., Ferrante, M., Calandrelli, R., Lazzaro, V. D., & Pilato, F. (2022) · Journal of Stroke · doi:10.5853/jos.2022.01410 · Cited by 41
Yang, Y.-K., Lin, C.-Y., Chen, P., & Jhou, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062267 · Cited by 40
Atrial Cardiomyopathy in Valvular Heart Disease: From Molecular Biology to Clinical Perspectives
Molnár, A. Á., Sánta, A., Pásztor, D. T., & Merkely, B. P. (2023) · Cells · doi:10.3390/cells12131796 · Cited by 36
Govori, V., Budinčević, H., Morović, S., Đerke, F., & Demarin, V. (2024) · Medicina · doi:10.3390/medicina60030504 · Cited by 38
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
Warach, S. J., Davis, L. A., Lawrence, P., Gajewski, B. J., Wick, J., Shi, F., Shang, T., Olson, D. M., Prasad, S., Birnbaum, L., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0285 · Cited by 36
Spence, J. D., Viscoli, C. M., Kernan, W. N., Young, L. H., Furie, K. L., DeFronzo, R. A., Abdul‐Ghani, M. A., Dandona, P., & Inzucchi, S. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14687 · Cited by 36
Self-citationDilaveris, P., Antoniou, C. K., Caiani, E. G., Casado-Arroyo, R., Climent, A. M., Cluitmans, M. J. M., Cowie, M., Doehner, W., Guerra, F., Jensen, M. T., et al. (2022) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztac026 · Cited by 40
Pathophysiology, diagnosis, and management of neuroinflammation in covid-19
Brown, R. L., Benjamin, L. A., Lunn, M. P., Bharucha, T., Zandi, M. S., Hoskote, C., McNamara, P., & Manji, H. (2023) · BMJ · doi:10.1136/bmj-2022-073923 · Cited by 37
Liang, H., Chen, X., Zhao, R., Li, S., Huang, P., Tang, Y., Cui, G.-H., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.021 · Cited by 36
Wang, M., Yan, H., Zhang, Y., Zhou, Q. G., Meng, X., Lin, J., Jiang, Y., Pan, Y., & Wang, Y. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105494 · Cited by 36
Sanchez‐Caro, J. M., de Ubago, I. D. L. M., Ruiz, E. D. C., Barguilla, A., Calvière, L., Raposo, N., Blancart, R. F. G., Fuentes, B., Díez‐Tejedor, E., & Rodríguez‐Pardo, J. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3989 · Cited by 35
Skrebelyte-Strøm, L., Rønning, O. M., Dahl, F. A., Steine, K., & Kjekshus, H. (2022) · EP Europace · doi:10.1093/europace/euac092 · Cited by 35
Carballo-Perich, L., Puigoriol‐Illamola, D., Bashir, S., Terceño, M., Silva, Y., Gubern, C., & Serena, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095149 · Cited by 33
Tran, K., Filippaios, A., Noorishirazi, K., Ding, E., Han, D., Mohagheghian, F., Dai, Q., Mehawej, J., Wang, Z., Lessard, D., et al. (2023) · Cardiology and Cardiovascular Medicine · doi:10.26502/fccm.92920314 · Cited by 35
Kasab, S. A., Nguyen, T. N., Derdeyn, C. P., Yaghi, S. R., Amin‐Hanjani, S., Kicielinski, K., Zaidat, O. O., & de Havenon, A. (2024) · Stroke · doi:10.1161/strokeaha.123.043635 · Cited by 34
Self-citationSacco, S., Foschi, M., Ornello, R., Santis, F. D., Pofi, R., & Romoli, M. (2024) · Diabetologia · doi:10.1007/s00125-024-06146-z · Cited by 41
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia
Gao, Y., Jiang, L., Pan, Y., Chen, W., Jing, J., Wang, C., Johnston, S. C., Amarenco, P., Bath, P. M., Yang, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1433 · Cited by 35
The most efficient machine learning algorithms in stroke prediction: A systematic review
Asadi, F., Rahimi, M., Daeechini, A. H., & Paghe, A. (2024) · Health Science Reports · doi:10.1002/hsr2.70062 · Cited by 42
Zheng, Z., Ke, L., Ye, S., Shi, P., & Yao, H. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s494555 · Cited by 34
Heo, J., Sim, Y., Kim, B. M., Kim, D. J., Kim, Y. D., Nam, H. S., Choi, Y. S., Lee, S., Kim, E. Y., & Sohn, B. (2024) · European Radiology · doi:10.1007/s00330-024-10618-6 · Cited by 33
Palaiodimou, L., Stefanou, M., Katsanos, A. H., Marchis, G. M. D., de Sousa, D. A., Dawson, J., Mira, K., Karapanayiotides, T., Toutouzas, K. G., Paciaroni, M., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241251931 · Cited by 33
Zhang, N., Zhou, Z., Chi, X., Fan, F., Li, S., Song, Y. M., Zhang, Y., Qin, X., Sun, N., Wang, X., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.034 · Cited by 36
Hemodynamic Stroke: Emerging Concepts, Risk Estimation, and Treatment
Wegener, S., Baron, J., Derdeyn, C. P., Fierstra, J., Fromm, A., Klijn, C. J. M., van Niftrik, C. H. B., & Schaafsma, J. D. (2024) · Stroke · doi:10.1161/strokeaha.123.044386 · Cited by 34
Hsieh, M., Hsieh, C., Tsai, T.-T., & Sung, S. (2022) · Clinical Epidemiology · doi:10.2147/clep.s353435 · Cited by 33
Ivancovsky Wajcman, D., Byrne, C. J., Dillon, J. F., Brennan, P. N., Villota-Rivas, M., Younossi, Z. M., Allen, A. M., Crespo, J., Gerber, L. H., & Lazarus, J. V. (2026) · Hepatology · doi:10.1097/hep.0000000000001058 · Cited by 33
Flink, M., Lindblom, S., von Koch, L., Carlsson, A. C., & Ytterberg, C. (2023) · Topics in Stroke Rehabilitation · doi:10.1080/10749357.2023.2178133 · Cited by 36
Age at cardiovascular disease onset, dementia risk, and the role of lifestyle factors
van Gennip, A. C. E., van Sloten, T. T., Fayossé, A., Sabia, S., & Singh‐Manoux, A. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13562 · Cited by 33
Spooner, M. T., Messe, S. R., Chaturvedi, S., Do, M. M., Gluckman, T. J., Han, J. K., Russo, A. M., Saxonhouse, S. J., & Wiggins, N. B. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.100 · Cited by 38
Self-citationBeyond “just” fun: The role of exergames in advancing health promotion and disease prevention
Manser, P., de Bruin, E. D., Temprado, J.-J., Bherer, L., & Herold, F. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106260 · Cited by 39
Atrial cardiomyopathy: markers and outcomes
Vad, O. B., van Vreeswijk, N. L., Yassin, A., Blaauw, Y., Paludan‐Müller, C., Kanters, J. K., Graff, C., Schotten, U., Benjamin, E. J., Svendsen, J. H., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf793 · Cited by 32
Current State of Stroke Care in Vietnam
Mai, D. T., Co, D. X., Luong, N. K., Nguyen, T. K., Nguyen, T. H., & Nguyen, T. N. (2022) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.121.000331 · Cited by 32
Self-citationLi, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 37
Gao, Y., Pan, Y., Han, S., Chen, W., Jing, J., Wang, C., Yang, Y., Wang, T., Meng, X., Zhao, X., et al. (2023) · Stroke and Vascular Neurology · doi:10.1136/svn-2022-002084 · Cited by 32
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Hsu, C., Saver, J. L., Ovbiagele, B. I., Wu, Y., Cheng, C.-Y., & Lee, M. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0218 · Cited by 33
Anghelescu, A., Firan, F. C., Onose, G., Munteanu, C., Vlădulescu-Trandafir, A.-I., Ciobanu, I., Gheorghița, Ș., & Ciobanu, V. (2023) · Biomedicines · doi:10.3390/biomedicines11061623 · Cited by 31
Tu, L., Melnick, E. R., Venkatesh, A. K., Sheth, K. N., Navaratnam, D. S., Yaesoubi, R., Forman, H. P., & Mahajan, A. K. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.23.30060 · Cited by 32
Improving Stroke Risk Factor Management Focusing on Health Disparities and Knowledge Gaps
Sur, N. B., Kozberg, M. G., Desvigne-Nickens, P. M., Silversides, C. K., Bushnell, C., Goldstein, L. B., Saver, J. L., Broderick, J. P., Gökçal, E., Merino, J. G., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.040449 · Cited by 36
Self-citationXian, Y., Li, S., Jiang, T., Beon, C., Poudel, R., Thomas, K., Reeves, M. J., Smith, E. E., Saver, J. L., Sheth, K. N., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.048174 · Cited by 31
Eapen, B. C., Tran, J., Ballard‐Hernandez, J., Buelt, A., Hoppes, C. W., Matthews, C. T., Pundik, S., Reston, J., Tchopev, Z. N., Wayman, L. M., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02205 · Cited by 34
Metadata
- Authors
- Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Turan, T. N., & Williams, L. S.
- ORCID
- Venue
- Stroke
- Published
- 2021-07
- Volume
- 52
- Issue
- 7
- Pages
- e364-e467
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W3164908038
- Semantic Scholar
- 18bb9d19bdfe54d5d1289c0a74fbcb410e3e1b6d
- Cited by
- 3,237
- References
- 892
- Citations by year
- 2026: 653 · 2025: 670 · 2024: 778 · 2023: 618 · 2022: 432 · 2021: 82
- FWCI
- 72.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-28)
- Open access
- bronze
- doi.org
- Locations
- Stroke (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Congress of Neurological Surgeons
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- secondary stroke prevention, stroke recurrence, transient ischemic attack, stroke risk factors
- MeSH terms
- Clinical Decision-Making, American Heart Association, Ischemic Attack, Transient, Humans, United States, Practice Guidelines as Topic, Stroke, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
